account_id none on file
legal_name Design Therapeutics, Inc.
ticker DSGN
cik 1807120
domain designtx.com
linkedin_company_url https://www.linkedin.com/company/designtx/about/
entry_point_account_id none on file
name Design Therapeutics Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 8 executives 1 family 0
why_nownone on file
callsnone on file
filings
In March 2020, the 2019 Consulting Agreement was terminated and replaced with an amended consulting agreement (the “2020 Consulting Agreement”), which provides for similar services and use of office space for a monthly fee of $ 20,000 .
filing / Aug 3, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.
filing / Aug 3, 2026 / receipt
In February 2021, the Company entered into a lease agreement with Crossing Holdings, LLC to rent laboratory and office space (the “Lease”).
filing / Aug 3, 2026 / receipt
Further, the adoption and implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for any approved product.
filing / Aug 3, 2026 / receipt
In March 2020, the 2019 Consulting Agreement was terminated and replaced with an amended consulting agreement (the “2020 Consulting Agreement”), which provides for similar services and use of office space for a monthly fee of $ 20,000 .
filing / Apr 28, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.
filing / Apr 28, 2026 / receipt
In February 2021, the Company entered into a lease agreement with Crossing Holdings, LLC to rent laboratory and office space (the “Lease”).
filing / Apr 28, 2026 / receipt
Further, the adoption and implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for any approved product.
filing / Apr 28, 2026 / receipt
executives
| Julie Burgess | Chief Accounting Officer | receipt |
familynone on file
upcoming
| 2026-11-04 | earnings call | scheduled | ir |
changes
| 2021-08-20 | Chief Accounting Officer, appointed | sec_8k |
mcp_package_hint
slug design-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$